What platelet concentration and yield should a PRP kit deliver for hair loss?

A fold number on its own tells you almost nothing about what reaches the scalp, because five times baseline in a patient starting at 180,000 is a different treatment from five times baseline in a patient starting at 350,000. What you're really buying is an absolute dose in a volume big enough to cover the thinning area, and a kit that hits a high fold while throwing most of the draw away hasn't given you that. Treat every published spec as a ceiling reached under ideal conditions and confirm it with real counts on your own prepared samples.

What baseline platelet count does whole blood provide, and what does concentration factor actually measure?

Baseline is the reference point every other number in a PRP spec is measured against, and it moves. The same patient can shift by tens of thousands between a morning and an afternoon draw depending on hydration, recent training, infection or where they are in a menstrual cycle, so a count borrowed from a previous visit or from a population average isn't a baseline at all.

• Normal range: 150,000 to 450,000 per microlitre, with most people near 200,000 to 300,000.
• The arithmetic: finished count divided by whole blood count, so 1,000,000 from 250,000 is four-fold.
• Same fold, different dose: four-fold reads 720,000 at a 180,000 baseline, 1,600,000 at 400,000.
• Draw ceiling: platelets aren't created in the centrifuge, so a scalp dose needs roughly 30 mL.

What platelet dose per treatment has clinical research linked to hair regrowth?

The trials that showed real density and thickness gains weren't chasing a fold figure, they were putting a countable number of platelets into a defined area of scalp. Dose framed that way is more useful to you than concentration alone, because a very concentrated two millilitre product spread thinly over a whole crown covers less biology per follicle than a moderately concentrated six millilitre product delivered to the same territory. The honest caveat is that many published studies never reported platelet counts at all, so there's no settled dose-response curve for hair the way there is for a drug.

How is platelet recovery efficiency calculated, and why does it matter more than fold concentration alone?

Fold is the easy number to publish and the easy number to sell, which is exactly why you should ask for recovery instead. A device that discards most of the plasma, or resuspends a small pellet in a tiny volume, can advertise an impressive six-fold product while handing back barely a third of what your patient gave up. Here's how you work out the number that actually matters.

1. Count what went in: baseline concentration times draw volume. 30 mL at 250,000 per microlitre is about 7.5 billion platelets.
2. Count what came out: final concentration times final volume. 5 mL at 1,100,000 per microlitre is 5.5 billion.
3. Divide one by the other: 5.5 billion out of 7.5 billion is roughly 73 percent recovery.
4. Benchmark it: well-tuned protocols reach 80 to 90 percent, while commercial automated systems commonly land at 40 to 60.
5. Read it back as burden: an 80 percent system hits a target dose from 30 mL where a 50 percent system needs closer to 50 mL.

Why does a higher concentration factor not always produce a better hair loss outcome?

This is where an impressive-sounding spec can quietly work against your patient. Dermal papilla cells bind growth factors through receptors that saturate, so once you're past roughly one to one and a half million platelets per microlitre you're adding signal with nothing left to receive it, and the alpha granule load of transforming growth factor beta that comes with it can push follicles toward catagen instead of holding them in anagen. Cell culture curves rise, flatten, and in some experiments turn back down.

How do leukocyte content and red cell carryover change what a stated concentration means?

A platelet count describes one cell line in a preparation that contains several, and the others change what your injection actually does. Two syringes both labelled a million platelets per microlitre can produce noticeably different swelling and soreness, and the difference is sitting in the cells nobody counted.

• Neutrophil load: they release proteases and reactive oxygen species you don't want around miniaturising follicles.
• Leukocyte-poor targets: neutrophils held below whole blood baseline, rather than harvested with the buffy coat.
• Monocytes and lymphocytes: viewed more neutrally, since monocyte signalling contributes to tissue remodelling.
• Red cell carryover: visible pink means a deep interface draw, then free haemoglobin and iron on lysis.

How do single-spin and double-spin systems differ in the concentration and yield they achieve?

The whole difference comes down to how many separation events your platelets pass through, and each one is another chance for activation, contamination and operator variation. Gel separators and buoy devices sit between the two, holding red cells down behind a density barrier during a single spin so the plasma decants cleanly, trading some ceiling concentration for consistency. For a busy scalp practice the real question isn't which protocol wins a validation study, it's which one your staff can reproduce identically on a Friday afternoon.

What final volume should a kit produce to treat a full scalp adequately?

Volume is the spec people skip past, and it's the one that decides whether the whole affected area gets treated at all. At one centimetre spacing and 0.05 to 0.1 millilitres per point, a hundred square centimetre area absorbs five to ten millilitres, and no amount of concentration makes up for having three millilitres to spread across it.

What patient-side and handling variables shift real yield away from a kit's advertised numbers?

Published kit performance is a best case: trained staff, healthy volunteer blood, a calibrated centrifuge. Every step between that and a real clinic day chips away at it, and the sensible expectation is that you land somewhat under the brochure figure. That's an argument for measuring what you get, not for distrusting the kit.

• Patient state: dehydration, recent viral illness or heavy training caps the achievable dose outright.
• The draw: small-gauge needles, long tourniquet time or a traumatic stick activate platelets in the tube.
• Anticoagulant and timing: too little citrate clots, too much dilutes, and delay costs growth factor payload.
• Operator judgement: where each person stops aspirating above the red cell interface swings yield run to run.

How can a clinic verify the concentration and yield its kit really delivers?

Verification is cheaper and simpler than most clinics assume, and it turns a brochure claim into a number you own. One run proves very little, so what you're after is the spread across patients and across every person on staff who prepares PRP, because that spread is usually more informative than the average.

1. Draw as usual: send a small aliquot of the whole blood for a standard complete blood count.
2. Process the rest exactly as you would for a patient: record the draw volume and the final volume as you go.
3. Count the product: send a well-mixed, unactivated aliquot for a platelet count on the same analyser, plus a leukocyte differential.
4. Repeat five to ten times: across different patients and across every staff member who prepares PRP.
5. Spot check afterwards: once or twice a year, after any centrifuge service, and whenever a new injector is trained.